TickerFacts.

Evommune, Inc. (EVMN): Revenue

Annual figures by period end, from SEC filings.

$13.00M
Year ended 2025-12-31
$10.00M
Trailing 12 months to 2026-06-30
2024-12-31: $7.00M2025-12-31: $13.00M$13.00M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$13.00M+85.7%2026-03-05, From 2025-01-01
2024-12-31$7.00Mn/a2026-03-05, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Evommune, Inc. (EVMN)2025-12-31$13.00M+85.7%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$13.11M+29.8%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$12.45M-25.2%
CV Sciences, Inc. (CVSI)2025-12-31$13.79M-12.2%
Pyxis Oncology, Inc. (PYXS)2025-12-31$13.86M-14.2%
Prelude Therapeutics Inc (PRLD)2025-12-31$12.14M+73.4%
Arbutus Biopharma Corp (ABUS)2025-12-31$14.08M+128.2%
Opus Genetics, Inc. (IRD)2025-12-31$14.20M+29.1%
Jaguar Health, Inc. (JAGX)2025-12-31$11.51M-1.5%

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗